Education
About Us
Working with TipRanks
Follow Us
Koninklijke Philips N.V. (PHG)
:PHG
Top Page
Koninklijke Philips
(NYSE:PHG)50Neutral
Koninklijke Philips (PHG) vs. S&P 500 (SPY)
Market Cap
$24.78B
Dividend YieldN/A
Average Volume (3M)903.00K
Price to Earnings (P/E)―
Beta (1Y)0.77
Revenue Growth-0.76%
EPS Growth-55.03%
CountryUS
Employees72,264
SectorHealthcare
Sector Strength74
IndustryMedical Equipment & Supplies
Share Statistics
EPS (TTM)-0.82
Shares Outstanding939,939,400
10 Day Avg. Volume1,439,984
30 Day Avg. Volume903,001
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.31
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$33.00Price Target Upside24.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Koninklijke Philips Business Overview & Revenue Model
Company DescriptionKoninklijke Philips N.V., commonly known as Philips, is a leading health technology company headquartered in the Netherlands. The company focuses on improving people's health and well-being through meaningful innovation in the areas of healthcare, consumer lifestyle, and lighting solutions. Philips operates through several segments, including Diagnosis & Treatment, Connected Care, and Personal Health, offering products such as imaging systems, patient monitoring devices, and personal health products like electric toothbrushes and grooming devices.
How the Company Makes MoneyPhilips generates revenue primarily through the sale of its innovative health technology products and services. The Diagnosis & Treatment segment contributes significantly to the company's earnings, offering advanced imaging systems, ultrasound, and healthcare informatics solutions to healthcare providers. The Connected Care segment provides patient monitoring and analytics services, while the Personal Health segment offers consumer health products such as oral care, grooming, and mother and child care products. Philips also engages in strategic partnerships and collaborations with hospitals, healthcare systems, and research institutions to enhance its product offerings and expand its market reach, further driving revenue growth.
Koninklijke Philips Financial Statement Overview
Summary
Koninklijke Philips is facing financial challenges with declining revenues and net losses. While the balance sheet is stable and cash flows are positive, profitability and equity remain under pressure. The company shows potential for recovery with operational improvements.Income Statement
Koninklijke Philips has experienced a declining revenue trend from its peak in 2020. The gross profit margin has also decreased over the years, indicating challenges in cost management or pricing power. The company has been suffering net losses in recent years, which impacts the net profit margin negatively. The EBIT margin is low, though there has been an improvement in the latest year, suggesting some operational recovery. Overall, the income statement reflects a company facing profitability challenges with some signs of stabilization.45
Neutral
Balance Sheet
The balance sheet shows a moderate debt-to-equity ratio, which suggests a balanced leverage position but with room for improvement. The equity ratio indicates a relatively stable financial foundation, though the decline in stockholders' equity over recent years could be a concern. Return on equity is negative due to net losses, highlighting the need for improved profitability. Overall, the balance sheet reveals a stable yet potentially vulnerable position due to ongoing losses.50
Neutral
Cash Flow
Philips has managed to generate positive operating cash flow, with free cash flow remaining positive recently, despite capital expenditures. The free cash flow growth rate has been fluctuating, reflecting challenges in maintaining consistent cash generation. The operating cash flow to net income ratio is healthy, indicating that cash generation is stronger than earnings performance would suggest. Overall, the cash flow statement shows resilience in cash management but underscores the need to enhance earnings quality.60
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 18.02B | 18.17B | 17.83B | 17.16B | 19.54B | Gross Profit |
| 7.77B | 7.45B | 7.19B | 7.17B | 8.78B | EBIT |
| 529.00M | -115.00M | -116.00M | 553.00M | 1.54B | EBITDA |
| 1.92B | 1.04B | 115.00M | 2.00B | 2.75B | Net Income Common Stockholders |
| -702.00M | -466.00M | -1.62B | 612.00M | 1.19B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 2.40B | 1.87B | 1.18B | 2.31B | 3.23B | Total Assets |
| 28.98B | 29.41B | 30.69B | 30.96B | 27.71B | Total Debt |
| 7.64B | 7.61B | 8.20B | 6.98B | 6.93B | Net Debt |
| 5.24B | 5.74B | 7.03B | 4.68B | 3.71B | Total Liabilities |
| 16.93B | 17.34B | 17.41B | 16.49B | 15.81B | Stockholders Equity |
| 12.01B | 12.03B | 13.25B | 14.44B | 11.87B |
| Cash Flow | Free Cash Flow | |||
| 893.00M | 1.49B | -979.00M | 866.00M | 1.83B | Operating Cash Flow |
| 1.56B | 2.14B | -173.00M | 1.63B | 2.78B | Investing Cash Flow |
| -573.00M | -636.00M | -1.49B | -3.67B | -1.32B | Financing Cash Flow |
| -496.00M | -848.00M | 500.00M | -2.35B | 483.00M |
Koninklijke Philips Technical Analysis
Neutral
26.55
Price Trends
26.32
Positive
27.14
Negative
27.68
Negative
Market Momentum
-0.13
Positive
49.33
Neutral
64.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHG, the sentiment is Neutral. The current price of 26.55 is below the 20-day moving average (MA) of 26.90, above the 50-day MA of 26.32, and below the 200-day MA of 27.68, indicating a neutral trend. The MACD of -0.13 indicates Positive momentum. The RSI at 49.33 is Neutral, neither overbought nor oversold. The STOCH value of 64.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PHG.
Koninklijke Philips Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | $148.79B | 50.24 | 14.51% | 0.82% | 10.23% | -5.74% | |
79 Outperform | $238.61B | 18.01 | 28.12% | 1.60% | 4.59% | 134.50% | |
77 Outperform | $119.32B | 28.28 | 8.63% | 2.96% | 2.72% | 4.48% | |
76 Outperform | $38.55B | 19.42 | 23.60% | 0.14% | 0.61% | 43.28% | |
73 Outperform | $65.60B | 37.95 | 6.85% | 1.70% | 5.89% | 42.05% | |
50 Neutral | $24.78B | ― | -5.85% | ― | -0.76% | -55.03% | |
49 Neutral | $7.05B | 0.34 | -55.09% | 2.46% | 25.27% | -3.43% |
* Healthcare Sector Average
Performance Comparison
PHG
Koninklijke Philips
26.55
6.86
34.84%
ABT
Abbott Laboratories
137.58
20.62
17.63%
BDX
Becton Dickinson
224.27
-7.40
-3.19%
MDT
Medtronic
93.03
10.31
12.46%
SYK
Stryker
389.92
38.16
10.85%
GEHC
GE Healthcare Technologies Inc
84.31
-8.65
-9.31%
Koninklijke Philips Earnings Call Summary
Earnings Call Date: Feb 19, 2025 | % Change Since: -6.22% | Next Earnings Date: May 6, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed picture with strong profitability and order growth outside China, driven by innovation and productivity savings. However, significant challenges remain, particularly with the continued impact of the Respironics recall and the substantial decline in China sales. The company's cautious outlook for 2025 reflects these ongoing challenges.Highlights
Strong Profitability and Cash Flow
The company delivered strong profitability improvement and cash flow in Q4 and for the full year 2024, with an adjusted EBITA margin increase of 90 basis points versus 2023.
Order and Sales Growth
Comparable order and sales grew low single digit in the quarter and the year, with orders growing 2% driven by strong growth in the US and in growth regions, despite a double-digit decline in China.
Productivity Savings and Innovation
Productivity savings of over EUR1.7 billion in the last two years, with innovations accounting for 50% of sales from new and upgraded products launched in the last three years.
Dividend Proposal
A dividend of EUR0.85 per share was proposed, payable in shares or cash, indicating confidence in the company's long-term plan and strong balance sheet.
AI-Driven Innovation
Introduction of AI-driven innovations such as the helium-free MRI scanner and strategic partnerships for imaging and health informatics platforms.
Lowlights
Decline in China Sales
China experienced a double-digit decline in sales, significantly impacting overall performance with expectations of continued mid- to high single-digit declines in 2025.
Respironics Recall Challenges
Continued challenges and high restructuring charges related to the Respironics recall, with additional costs expected in 2025.
Net Income Decrease
Net income decreased by EUR371 million in the quarter due to higher tax expenses, write-down of intangible assets, and restructuring charges.
High Restructuring and Other Charges
High restructuring and other charges due to efforts in resolving the Respironics recall and operational changes.
Company Guidance
During the Royal Philips fourth quarter and full year 2024 results conference call, CEO Roy Jakobs and CFO Charlotte Hanneman highlighted several key metrics and strategic priorities. They reported a 1% growth in comparable sales and orders for the full year, with a notable 5% growth in the rest of the world, countering a double-digit decline in China. The adjusted EBITA margin improved by 90 basis points to 11.5% for the full year, with a strong free cash flow of EUR 0.9 billion. The company achieved productivity savings of over EUR 1.7 billion over the past two years and plans to increase savings targets to EUR 2.5 billion by 2025. They anticipate 1% to 3% sales growth in 2025, despite ongoing challenges in China, and expect margin expansion of 30 to 80 basis points, driven by continuous investment in innovations and operational improvements. Philips proposed a dividend of EUR 0.85 per share, payable in shares or cash, reflecting their robust balance sheet. The company remains focused on resolving the Respironics recall and enhancing supply chain efficiency, while leveraging AI-driven innovations to maintain its market position.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.